Literature DB >> 3086278

In-vitro activity of pefloxacin against micro-organisms multiply resistant to beta-lactam antibiotics and aminoglycosides.

L Verbist.   

Abstract

The in-vitro activity of pefloxacin was evaluated against 360 Enterobacteriaceae, 143 Pseudomonas aeruginosa and 124 staphylococci, selected for multiply resistance to different beta-lactam antibiotics and aminoglycosides. The MIC90 of pefloxacin against staphylococci and most Enterobacteriaceae was 0.5 mg/l or less. The MIC90 against Serratia marcescens and P. aeruginosa varied between 4 and 8 mg/l. Time-killing curves showed that pefloxacin at concentrations of four times the MIC decreased the viable counts by 3 logs or more within 1-8 h.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086278     DOI: 10.1093/jac/17.suppl_b.11

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  11 in total

1.  Penetration of pefloxacin into maxillary sinus cavity and nasal secretions.

Authors:  G Petrikkos; P Goumas; E Moschovakis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

2.  Clinical experience with pefloxacin in the therapy of typhoid fever.

Authors:  P Cristiano; G Morelli; V Briante; M R Iovene; F Simioli; P Altucci
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

3.  Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C Thauvin; J F Lemeland; G Humbert; J P Fillastre
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

4.  Intraperitoneal penetration of pefloxacin.

Authors:  J M Webberly; I Donovan; R Wise; J Ashby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

5.  Topical pefloxacin in bacterial keratitis.

Authors:  R B Vajpayee; N Sharma; B Verma; M Vajpayee; S K Gupta; G Satpathy; R Saxena
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

6.  Pefloxacin versus ceftazidime in the treatment of a variety of gram-negative-bacterial infections.

Authors:  H Giamarellou; G Perdikaris; N Galanakis; G Davoulos; K Mandragos; P Sfikakis
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 7.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

8.  Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).

Authors:  G Verschraegen; G Claeys; A M Van den Abeele
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

9.  Multiple-dose pharmacokinetics of pefloxacin in patients with hepatocellular deficiency.

Authors:  M Galtier; F Bressolle; J E de la Coussaye; R Gomeni; P Joubert; F Gény; A Dubois; C Raffanel; G Saissi; J J Eledjam
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

10.  Pharmacokinetics and tissue penetration of orally administered pefloxacin.

Authors:  J M Webberley; J M Andrews; J P Ashby; A McLeod; R Wise
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.